Search Results - "Gutiérrez, MDM García"

4CPS-155 Comparative study for evaluation of the pain, ease of use and preference between two adalimumab administration devices: study adap2017 by Muñoz, N Herrero, Rosado, A Andrés, Muniesa, B Hernández, Lázaro, C Bravo, Román, AB Fernández, Alonso, A Pou, Nasarre, A Ontañón, Gutiérrez, MDM García, López, C Mayo, Gil, M García

“…BackgroundAdalimumab is a monoclonal antibody indicated in immunomediate inflammatory diseases for subcutaneous administration by two different devices:…”
Get full text

4CPS-091 Analysis of pharmaceutical interventions related to high-risk-drugs in the emergency department by Rico-Pizarro, L, Moreno-Gutiérrez, L, Puivecino-Moreno, C, Castellanos-Clemente, Y, García-Gutiérrez, MDM, Font-Tarres, N, García-Gil, M

“…Background and importanceMedication errors are frequent in the emergency department (ED) and the most common drugs involved are high-risk-drugs (HRD), which…”
Get full text

4CPS-219 Analysis of pharmaceutical interventions in an emergency department by Fernandez Roman, AB, Mariño Martinez, C, Martin Lopez, M, Herrero Muñoz, N, Garcia Gutierrez, MDM, Garcia Gil, M

“…BackgroundMedication errors in the emergency department can persist throughout the episode of care and up to hospital discharge, leading to inadequate…”
Get full text

1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting by Román, AB Fernández, Lázaro, C Bravo, Fernández, J Letellez, Muñoz, N Herrero, Rosado, A Andrés, Lopez, C Mayo, Gutierrez, MDM Garcia, Gil, M Garcia

“…BackgroundNivolumab (NIV) is a monoclonal antibody for patients with pre-treated advanced nonsquamous non–small-cell lung cancer (NSCLC). It is necessary to…”
Get full text